PMID- 14529943
OWN - NLM
STAT- MEDLINE
DCOM- 20040708
LR  - 20211203
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 35
IP  - 6
DP  - 2003 Sep
TI  - The emerging matrix of immunosuppressive agents.
PG  - 2365-8
AB  - In recent years, significant milestones have been reached in the field of 
      transplantation through the development of immunosuppressive drugs that inhibit 
      lymphocyte activation, cytokine signal transduction, and cellular proliferation. 
      However, the widespread tissue distribution of the molecular targets exploited to 
      date-calcineurin, mammalian target of rapamycin (mTOR), and inosine monophosphate 
      dehydrogenase-produces an array of collateral toxicities. Avoiding these side 
      effects requires new strategies that selectively block destructive immune 
      responses: a fifth generation of immunosuppressants. These agents must target 
      molecules that are critical for and specific to the adaptive immune response.
FAU - Kahan, B D
AU  - Kahan BD
AD  - Department of Surgery, University of Texas Medical School, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Cytokines)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantigens)
SB  - IM
MH  - Animals
MH  - Antigen-Presenting Cells/immunology
MH  - Cell Adhesion/immunology
MH  - Cell Movement/immunology
MH  - Cytokines/immunology
MH  - Humans
MH  - Immunosuppression Therapy/*trends
MH  - *Immunosuppressive Agents
MH  - Isoantigens/immunology
MH  - Lymphocyte Depletion
RF  - 58
EDAT- 2003/10/08 05:00
MHDA- 2004/07/09 05:00
CRDT- 2003/10/08 05:00
PHST- 2003/10/08 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2003/10/08 05:00 [entrez]
AID - S0041134503008376 [pii]
AID - 10.1016/s0041-1345(03)00837-6 [doi]
PST - ppublish
SO  - Transplant Proc. 2003 Sep;35(6):2365-8. doi: 10.1016/s0041-1345(03)00837-6.